No Data
No Data
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
HEAR, SOUN and WW Are Among After Hour Movers
What's Going On With Kintara Therapeutics Stock?
Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares are volatile Wednesday after the company announced it is seeking withdrawal of its registration statement for a public offering of securities.The Detail
HRTX, LUNA and ARQ Among Mid-day Movers
Kintara Therapeutics Bounces Back
Kintara Therapeutics (KTRA) Sees Market Recovery Post Friday Downturn
Shares of Kintara Therapeutics, Inc. (Nasdaq: KTRA) experienced a sluggish trading session on Friday, dipping nearly 5%. However, the pre-market session today hints at a slight rebound, showing a 2% increase. Key Corporate Updates Kintara, a company specializing in cancer therapies, recently unveiled significant developments: Initiation of REM-001 Study Kintara commenced an open-label study evaluating ...
No Data